Aug 5, 2026Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
Jul 22, 2026Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
Jul 22, 2026Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
Jul 21, 2026Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
Jul 1, 2026New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
Jun 3, 2026Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
May 26, 2026Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 5, 2026Arcus Biosciences Reports First-Quarter 2026 Financial Results and Provides a Pipeline Update
Apr 21, 2026Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2026 Financial Results and Pipeline Updates
